Exthymic

About Exthymic

Exthymic, founded in 2023 by serial bioengineering entrepreneur Rich Stoner, is a biotechnology company operating in stealth mode from its San Diego, California headquarters. The company is focused on democratizing access to autologous cell therapies by developing a point-of-care manufacturing platform. This approach aims to address the significant logistical hurdles, high costs, and limited patient access associated with the current centralized manufacturing model for treatments like CAR-T therapy.

The company's establishment is a culmination of its founder's extensive experience at the intersection of biology and engineering. Stoner, who holds a Ph.D. in bioengineering, previously served as the founding Chief Scientific Officer at Resilience, a major biomanufacturing startup, and as CSO for CRISPR genome engineering company Synthego. His career has been dedicated to pioneering new technologies, including building multidisciplinary research teams and launching web-based CRISPR design and analysis software tools. This background provides a strong foundation for tackling the complex challenge of decentralized cell therapy production.

Exthymic's core mission is to shift the production of patient-specific therapies from large, centralized facilities to a localized setting, closer to the patient. The current process often involves transporting a patient's cells to a manufacturing site and back, a journey that can take weeks and is resource-intensive. By enabling manufacturing at or near the treatment center, Exthymic intends to significantly reduce these turnaround times and logistical complexities. While specific details of its technology remain under wraps, the company is associated with a patent for microfluidic devices designed for high-throughput single-cell analysis, suggesting a potential direction for its platform. Having secured $10.2 million in an early-stage venture funding round in May 2024, the company is capitalized to advance its development efforts.